How much funding has Protai raised?

Protai has raised $8.0M in total funding, most recently a Seed round.

Where is Protai headquartered?

Protai is headquartered in Tel Aviv, Israel.

What industry is Protai in?

Protai operates in Artificial Intelligence, Biotech.

Protai

Q: Who are Protai's investors?

Protai's investors include Grove Ventures, Pitango Growth, Maj Invest.

Proteomics & AI Drug Discovery

Tel Aviv, Israel · Founded 2021 · $8.0M raised

Artificial Intelligence

Biotech

Headquarters: Tel Aviv
Employees: 11–50
Founded: 2021
Business Model: B2B

Website: protai.bio
Total Funding: $8.0M
Last Round: SeedMar 2023
Rounds: 2

About

Founded in 2021 by CEO Eran Seger and CTO Kirill Pevzner, Protai is an Israeli biotech company headquartered in Tel Aviv. The company has built an end-to-end AI platform that comprehensively maps disease progression at the protein level, combining structural and functional proteomics with machine learning to identify up to 1 million proteoforms. Protai raised an $8M seed round to develop its proteomics-based drug discovery platform, and uses advanced protein simulations to discover novel medicines for cancer and other complex diseases. The company leverages AlphaFold and NVIDIA NIM for complex structure prediction.

Summary

Protai is an Artificial Intelligence company based in Tel Aviv, Israel, founded in 2021. It has raised $8.0M in total across 2 rounds, most recently a Seed round in Mar 2023. Investors include Grove Ventures, Pitango Growth and Maj Invest.